Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis
- PMID: 15488763
- DOI: 10.1016/j.ccr.2004.08.031
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis
Abstract
We demonstrate a novel tumor-promoting role of myeloid immune suppressor Gr+CD11b+ cells, which are evident in cancer patients and tumor-bearing animals. These cells constitute approximately 5% of total cells in tumors. Tumors coinjected with Gr+CD11b+ cells exhibited increased vascular density, vascular maturation, and decreased necrosis. These immune cells produce high levels of MMP9. Deletion of MMP9 in these cells completely abolishes their tumor-promoting ability. Gr+CD11b+ cells were also found to directly incorporate into tumor endothelium. Consistent with this observation, Gr+CD11b+ cells acquire endothelial cell (EC) properties in tumor microenvironment and proangiogenic culture conditions. Our data provide evidence that Gr+CD11b+ cells of immune origin induced by tumors directly contribute to tumor growth and vascularization by producing MMP9 and differentiating into ECs.
Similar articles
-
Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.Eur J Immunol. 2010 Jan;40(1):22-35. doi: 10.1002/eji.200939903. Eur J Immunol. 2010. PMID: 19941314
-
Tumor-conditioned Gr-1(+)CD11b(+) myeloid cells induce angiogenesis through the synergistic action of CCL2 and CXCL16 in vitro.Biochem Biophys Res Commun. 2014 Jan 24;443(4):1218-25. doi: 10.1016/j.bbrc.2013.12.117. Epub 2014 Jan 2. Biochem Biophys Res Commun. 2014. PMID: 24388986
-
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells.Cancer Res. 2006 Jul 1;66(13):6807-15. doi: 10.1158/0008-5472.CAN-05-3755. Cancer Res. 2006. PMID: 16818658
-
Myeloid-derived suppressor cell heterogeneity and subset definition.Curr Opin Immunol. 2010 Apr;22(2):238-44. doi: 10.1016/j.coi.2010.01.021. Epub 2010 Feb 17. Curr Opin Immunol. 2010. PMID: 20171075 Review.
-
Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells.Cancer Res. 2008 Jul 15;68(14):5501-4. doi: 10.1158/0008-5472.CAN-08-0925. Cancer Res. 2008. PMID: 18632597 Review.
Cited by
-
Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs.Front Cell Dev Biol. 2020 Jul 7;8:584. doi: 10.3389/fcell.2020.00584. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32775327 Free PMC article. Review.
-
Tumour and patient factors in renal cell carcinoma-towards personalized therapy.Nat Rev Urol. 2015 May;12(5):253-62. doi: 10.1038/nrurol.2015.71. Epub 2015 Apr 14. Nat Rev Urol. 2015. PMID: 25868564 Review.
-
The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis.PLoS One. 2016 Oct 25;11(10):e0164514. doi: 10.1371/journal.pone.0164514. eCollection 2016. PLoS One. 2016. PMID: 27780254 Free PMC article.
-
Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer.Biomed Res Int. 2015;2015:794968. doi: 10.1155/2015/794968. Epub 2015 Jun 16. Biomed Res Int. 2015. PMID: 26161414 Free PMC article. Review.
-
The immune landscape of hepatocellular carcinoma-where we are?Oncol Lett. 2022 Sep 27;24(5):410. doi: 10.3892/ol.2022.13530. eCollection 2022 Nov. Oncol Lett. 2022. PMID: 36245826 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous